Qili Qiangxin capsule as adjunctive therapy for heart failure after acute myocardial infarction: a GRADE-assessed systematic review and meta-analysis of randomised controlled trials
10 affiliations
- 1Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine
- 2School of Medicine, Shandong University of Traditional Chinese Medicine
- 3Cardiovascular Disease Center, Affiliated Hospital of Shandong University of Traditional Chinese Medicine
- 4Science and Technology Department, Affiliated Hospital of Shandong University of Traditional Chinese Medicine
- 5Institute of Health and Social Care, London South Bank University
- 6Centre for Evidence-Based Medicine, Hospital of Chengdu University of Traditional Chinese Medicine
- 7Sichuan Provincial Centre for Evidence-Based Chinese Medicine, Hospital of Chengdu University of Traditional Chinese Medicine
- 8Clinical Study Center, Affiliated Hospital of Shandong University of Traditional Chinese Medicine
- 9Centre for Evidence-Based Chinese Medicine, Shandong University of Traditional Chinese Medicine
- 10Shandong Big Data Research Association
Abstract
Background: Heart failure (HF) after acute myocardial infarction (AMI) remains a major cause of morbidity and mortality despite advances in conventional therapy. Qili Qiangxin Capsule (QLQX) has been widely used as an adjunctive treatment for HF in China, but its efficacy and safety in patients with HF after AMI require further evaluation.
Methods: Seven databases were searched from their inception to January 2026. Randomised controlled trials (RCTs) comparing QLQX plus conventional Western medicine (WM) with WM alone were included. The primary outcome was N-terminal pro-B-type natriuretic peptide (NT-proBNP). Secondary outcomes included left ventricular ejection fraction (LVEF), B-type natriuretic peptide (BNP), left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD), left ventricular end-diastolic volume (LVEDV), clinical response rate, high-sensitivity C-reactive protein (hs-CRP), quality of life, all-cause mortality, heart failure-related hospitalisation, and adverse events. Meta-analysis was performed using RevMan 5.4.
Results: A total of 16 RCTs involving 1391 participants were included. Compared with WM alone, QLQX plus WM was associated with greater reductions in NT-proBNP, BNP, LVEDD, LVESD, and hs-CRP, and improving LVEF, quality of life and the clinical response rate. No statistical differences were observed in LVEDV, all-cause mortality, and adverse events. Heart failure-related hospitalisation was not reported in any included study. The certainty of evidence for all outcomes was rated as low or very low according to the GRADE approach.
Conclusion: QLQX plus conventional WM was associated with improvements in several surrogate and short-term clinical outcomes in patients with HF after AMI. However, the certainty of evidence was low or very low, and data on mortality and heart failure-related hospitalisation were insufficient. The current evidence is therefore inadequate to determine whether QLQX improves long-term clinical prognosis. Further high-quality RCTs with longer follow-up and clinically important endpoints are needed.
Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261277047 , identifier CRD420261277047.
Related
- Cost-effectiveness of adjunctive hyperbaric oxygen therapy for fibromyalgia: an economic evaluation alongside a single-centre randomised controlled trial in Brazil
- Effects of adjunctive tirofiban during PCI on myocardial perfusion and ventricular function in myocardial infarction: a 3D echocardiography-based evaluation
- Adjunctive Low-Dose Acetylsalicylic Acid in Bipolar Disorder: A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase II Trial (ASPIRIN BD)
- Hemodynamic Changes and Anxiety-Related Outcomes Following Hand Reflexology in Patients with Acute Myocardial Infarction: A Randomized Controlled Trial
- Risk of myocardial infarction in adults with gout treated with allopurinol: A systematic review and meta-analysis
BibTeX
@article{yu2026qili,
title = {{Qili Qiangxin capsule as adjunctive therapy for heart failure after acute myocardial infarction: a GRADE-assessed systematic review and meta-analysis of randomised controlled trials}},
author = {Jun-Hong Yu and Hao-Yu Yu and Jun-Cheng Zhang and Zhao-Yang Chen and Cong Wang and You-Qi Wu and Yi-Fei Wang and Nicola Robinson and Jian-Ping Liu and Yun-Lun Li and Shi-Bing Liang},
journal = {Frontiers in Pharmacology},
year = {2026},
month = oct,
doi = {10.3389/fphar.2026.1959187},
url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1959187/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Qili Qiangxin capsule as adjunctive therapy for heart failure after acute myocardial infarction: a GRADE-assessed systematic review and meta-analysis of randomised controlled trials
AU - Jun-Hong Yu
AU - Hao-Yu Yu
AU - Jun-Cheng Zhang
AU - Zhao-Yang Chen
AU - Cong Wang
AU - You-Qi Wu
AU - Yi-Fei Wang
AU - Nicola Robinson
AU - Jian-Ping Liu
AU - Yun-Lun Li
AU - Shi-Bing Liang
PY - 2026
DA - 2026/10/19
JO - Frontiers in Pharmacology
DO - 10.3389/fphar.2026.1959187
UR - https://www.frontiersin.org/articles/10.3389/fphar.2026.1959187/full
AB - Background: Heart failure (HF) after acute myocardial infarction (AMI) remains a major cause of morbidity and mortality despite advances in conventional therapy. Qili Qiangxin Capsule (QLQX) has been widely used as an adjunctive treatment for HF in China, but its efficacy and safety in patients with HF after AMI require further evaluation. Methods: Seven databases were searched from their inception to January 2026. Randomised controlled trials (RCTs) comparing QLQX plus conventional Western medicine (WM) with WM alone were included. The primary outcome was N-terminal pro-B-type natriuretic peptide (NT-proBNP). Secondary outcomes included left ventricular ejection fraction (LVEF), B-type natriuretic peptide (BNP), left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD), left ventricular end-diastolic volume (LVEDV), clinical response rate, high-sensitivity C-reactive protein (hs-CRP), quality of life, all-cause mortality, heart failure-related hospitalisation, and adverse events. Meta-analysis was performed using RevMan 5.4. Results: A total of 16 RCTs involving 1391 participants were included. Compared with WM alone, QLQX plus WM was associated with greater reductions in NT-proBNP, BNP, LVEDD, LVESD, and hs-CRP, and improving LVEF, quality of life and the clinical response rate. No statistical differences were observed in LVEDV, all-cause mortality, and adverse events. Heart failure-related hospitalisation was not reported in any included study. The certainty of evidence for all outcomes was rated as low or very low according to the GRADE approach. Conclusion: QLQX plus conventional WM was associated with improvements in several surrogate and short-term clinical outcomes in patients with HF after AMI. However, the certainty of evidence was low or very low, and data on mortality and heart failure-related hospitalisation were insufficient. The current evidence is therefore inadequate to determine whether QLQX improves long-term clinical prognosis. Further high-quality RCTs with longer follow-up and clinically important endpoints are needed. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261277047 , identifier CRD420261277047.
SN - 1663-9812
ER -